What Alveo Technologies does

Alveo Technologies is a private molecular diagnostics company that has developed the Alveo Sense platform — a portable, palm-sized nucleic acid amplification testing (NAAT) system built around a patented method of direct electrical impedance sensing of loop-mediated isothermal amplification (LAMP). The platform eliminates the complex optics used in conventional PCR instruments and is engineered as a solid-state, no-moving-parts aluminum analyzer paired with single-use QR-coded test cartridges (with dried-down reagents and internal process controls) and a Bluetooth-connected iOS/Android mobile app that uploads time- and geo-tagged results to the Alveo Vista cloud portal (Level 3 encryption, 2FA). The system delivers lab-grade molecular results in approximately 45 minutes at the point of need, replacing 2-5 day centralized lab turnaround. Product variants include the Alveo Sense Poultry Avian Influenza Test (H5/H7/H9 multiplex), be.well® for human point-of-care respiratory diagnostics, and an open co-development platform for partners to develop viral, bacterial and fungal assays.

Alveo generates revenue through a razor-and-blade model: one-time sales of the Alveo Analyzer, recurring pull-through consumable cartridge sales, enterprise subscriptions for the Alveo Sense app and Alveo Vista portal, and co-development/licensing partnerships with veterinary, agricultural and bioprocessing organizations; non-dilutive CEPI grant funding supplements R&D. Distribution combines direct enterprise sales with a 23+ country network of named regional distributors across Europe, the Middle East and Africa, anchored by flagship co-development partners Royal GD (Netherlands, veterinary laboratory running 5M+ tests/year) and Global Animal Health (MENA, with a national-scale 1,000-analyzer/10,000-cartridge deployment in Egypt announced December 2025). The company is ISO 13485 certified, CE marked for IVD kits and analyzers, and holds 59 global patents (issued, published or pending) on its core sensing method. Customer segments span animal health (poultry, livestock, companion animals), agriculture and food & beverage, environmental and wastewater surveillance, bioprocess and vaccine manufacturing QC, and human public health.

The company is headquartered in Alameda, California, with 51-100 employees, and is led by CEO Shaun Holt (ex-Illumina, Berkeley Lights, Atonarp), President and CBO Erik Tyrrell-Knott (ex-Thermo Fisher, Mesa Biotech, Atonarp), and CCO Scott Thomas (ex-Illumina, Roche Molecular Diagnostics, Singular Genomics, Seer Bio). Approximately $54 million has been raised across a 2018 round led by Maxim Group with Celesta Capital and Civilization Ventures (~ $38M) and a 2021 round led by Black Diamond Ventures (~$16M), supplemented by a 2026 CEPI development grant for vaccine-manufacturing applications.

Name

Alveo Technologies

Legal name

Alveo Technologies, Inc.

Website

https://alveotechnologies.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

51–100 employees

Short description

Alveo Technologies builds a palm-sized, portable molecular diagnostic platform (Alveo Sense) using patented direct electrical sensing of nucleic acid amplification, delivering lab-grade results in 45 minutes at the point of need for animal health, agriculture, food safety, bioprocessing, and human health customers across 23+ countries.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

akta.pro secondary industries

SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE), AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

Keywords

• Molecular diagnostics
• Avian influenza testing
• Portable PCR devices
• Point-of-care diagnostics
• Veterinary diagnostics

Headquarters

HQ city

Alameda

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Hardware Sales (Alveo Analyzer): One-time capital equipment sale of the palm-sized, rechargeable Alveo Analyzer (Part Number A-FIN-000039) bundled with USB charging cable and region-specific power adapters. Sold through direct enterprise sales and authorized country distributors.
2. Recurring Consumable Test Cartridge Sales: Recurring pull-through revenue from sale of test-specific Alveo Sense Cartridges (e.g., Avian Influenza Type A/H5/H7 or Type A/H5/H9 panels) consumed with each test run. The Egypt national-scale deployment alone shipped 10,000 test cartridges alongside 1,000 analyzers.
3. Enterprise Subscription for Software Services (be.well / Alveo Sense App / Alveo Vista): Enterprise customers (e.g., healthcare providers, veterinary organizations) pay or commit to pay a subscription for use of the Services (smartphone app, online platform, cloud data portal). Authorized User access to the Services is dependent on full and timely payment by the affiliated Enterprise Customer.
4. Co-Development and Deployment Partnerships: Strategic collaboration with partners such as Royal GD (Netherlands) and Global Animal Health for joint commercialization, distribution, and expanded testing portfolio development beyond avian influenza. Includes joint go-to-market programs under a Partner Portal structured around Research Use Only and Deployment Partnership tracks.
5. Grant and Non-Dilutive Funding (CEPI): Non-dilutive development grant funding from organizations such as the Coalition for Epidemic Preparedness Innovations (CEPI) to explore applying the platform to vaccine manufacturing in-process and QC testing.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels9 records

Core offering

Alveo Technologies develops and sells the Alveo Sense™ portable molecular diagnostic platform, anchored by a patented palm-sized Alveo Analyzer that uses direct-electrical-impedance sensing of LAMP-based nucleic-acid amplification. The platform pairs single-use QR-coded test cartridges (initial focus on avian influenza H5/H7/H9 multiplexed panels) with the Alveo Sense mobile app and the Alveo Vista cloud data portal. Its commercial offering extends to the be.well® human point-of-care respiratory diagnostic system and an open development platform that enables partners to co-develop new viral, bacterial, and fungal assays for animal health, agriculture, food and beverage, environmental, and bioprocessing applications.

Product overview

Alveo Technologies offers a platform-plus-modules architecture centered on the Alveo Sense™ portable molecular diagnostic platform. The core platform consists of three integrated components: the Alveo Analyzer (a palm-sized, reusable IVD hardware instrument), Alveo Sense Cartridges (single-use, QR-coded test cartridges), and the Alveo Sense Mobile App (a Bluetooth-connected smartphone application). These are complemented by the Alveo Vista™ centralized data analytics portal, which provides cloud-based geotagging, timestamping, and analytics. Built on this platform are specific products including the Alveo Sense Poultry Avian Influenza Test (an H5/H7/H9 multiplexed assay for poultry surveillance), be.well® (a point-of-care respiratory diagnostic system for human health), and an open development platform that enables partners to co-develop new assays for viral, bacterial, and fungal pathogens across animal health, agriculture, environment, food and beverage, and bio-monitoring use cases.

Differentiator

Problem solved

Functional benefit

Brands

• Alveo Sense™: Portable, multiplex-capable molecular diagnostic platform employing a patented method of direct electrical sensing of nucleic acid amplification; marketed across animal health, agriculture, food safety, environment, bioprocessing, and human health use cases.
• be.well®
• Alveo Vista™
• Alveo Analyzer

Products and services

• Alveo Analyzer A standalone, palm-sized, portable, and rechargeable in vitro diagnostic instrument that accepts test-specific Alveo Sense Cartridges and executes nucleic acid amplification and detection using a patented direct electrical sensing method (LAMP-based). It has no moving parts, is housed in a unitary aluminum shell, and pairs with a smartphone via Bluetooth to display test results. It is sold to enterprise customers in animal health, agriculture, public health, bioprocessing, and human health applications.
• Alveo Sense Cartridges Preloaded single-use cartridges with a QR code for secure, automated test registration and result tracking. Reagents for each assay are dried down and packaged with a desiccant for shelf stability, and each cartridge includes internal process controls to ensure tests are run properly. Cartridges support multiplex testing (for example, Avian Influenza Type A with H5/H7 or H9 differentiation) and generate recurring consumable revenue.
• Alveo Sense Poultry Avian Influenza Test A specific test kit using the Alveo Sense platform to detect notifiable Avian Influenza viruses (H5 and H7 subtypes) and the major global endemic strain (H9 subtype), with multiplex differentiation of H5 and H7 or H9 subtypes via direct electrical sensing of nucleic acid amplification. Delivers laboratory-grade results in approximately 45 minutes via the Alveo Sense mobile app for poultry producers, integrators, veterinarians, and regulators managing outbreak containment and routine surveillance.
• be.well® Human Point-of-Care Diagnostic System Alveo's branded healthcare solution that brings rapid, accurate molecular diagnostics to clinics, medical offices, and pharmacies. It uses nucleic acid amplification technology to detect a wide range of diseases, bacteria, and other pathogens at the point of care, with an initial focus on respiratory pathogens such as seasonal influenza and Influenza A(H5) (supported by a fulfilled CDC milestone agreement). Sold to healthcare providers, pharmacies, and public-health agencies.
• Alveo Sense Open Development Platform (Assay Co-Development) An open-platform program that allows partners to co-develop new molecular assays on the Alveo Sense platform. It supports development across viral, bacterial, and fungal pathogen types and across multiple industries (animal health, agriculture, environment, food and beverage, bio-monitoring). Partners access program resources, technical documentation, and collaboration tools through the Partner Portal, including separate Research Use Only and Deployment Partnership tracks.
• Alveo Vista Centralized Data Portal A cloud-based, centralized data portal that automatically geotags and timestamps test results from the Alveo Analyzer and uploads them in real time over Bluetooth for secure, centralized analytics. Access is limited to credentialed users and protected by Level 3 encryption and 2-factor authentication; results can be exported to regulatory agencies and state veterinarians for surveillance and audit. Sold to enterprise customers under an annual subscription.

Quantifiable outcome

• 45 minutes to presumptive positive result in on-farm avian influenza testing
• +7 more outcomes

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

17 partnerships are on record, tiered major non-dilutive funding / strategic validation partner, targeted co-development partnership, flagship / core strategic partner, validation / reference partner, core scientific validation partner, major reference / validation partner, authorized media relations partner, country distributor (albania), country distributor (baltics), country distributor (hungary), country distributor (montenegro), country distributor (kuwait), country distributor (pakistan), country distributor (qatar), country distributor (morocco) and country distributor (tunisia).

• Coalition for Epidemic Preparedness Innovations (CEPI)major non-dilutive funding / strategic validation partnerOthers · 26 May 2026CEPI awarded Alveo a development grant to explore applying its palm-sized NAAT analyzer, mobile app, and centralized data analytics portal to vaccine manufacturing in-process and QC testing. Marks Alveo's expansion beyond infectious disease diagnostics into the vaccine manufacturing market, supporting animal and human health.
• Fraunhofer Institutetargeted co-development partnershipStrategic or Co-development Partner · 9 April 2026Co-developing a rapid molecular diagnostic panel for feline respiratory infections, detecting feline influenza, FCV (feline calicivirus), and FHV (feline herpesvirus). The test is intended for shelters, veterinary clinics, and boarding environments to enable faster diagnosis and treatment.
• Global Animal Health (GAH)flagship / core strategic partnerStrategic or Co-development Partner · 18 December 2025Strategic partnership to deploy Alveo's Alveo Sense Poultry Avian Influenza Test at national scale across Egypt - the first mass-scale use of on-site real-time molecular diagnostics for poultry disease monitoring globally. Initial deployment of 1,000 analyzers and 10,000 test cartridges covering ~10% of farms along major migratory bird flyways, with plans to expand across the Middle East and North Africa. Results delivered in approximately 45 minutes with wireless real-time data upload. GAH also serves as Alveo's distributor across Bahrain, Egypt, Oman, and Saudi Arabia.
• U.S. Department of Energy Joint Genome Institute (JGI), Lawrence Berkeley National Laboratoryvalidation / reference partnerTechnology or Integration · 23 October 2025JGI evaluated Alveo's portable Alveo Sense™ molecular testing platform for wastewater-based pathogen surveillance, demonstrating feasibility for rapid, on-site infectious disease monitoring. Validation expands potential applications of the platform beyond laboratory settings.
• Poultry Diagnostics Research Center (PDRC), University of Georgia College of Veterinary Medicinecore scientific validation partnerStrategic or Co-development Partner · 5 August 2025Two-phase research study validating Alveo Sense Poultry Avian Influenza Test performance in detecting high and low pathogenic H5N1 in experimentally infected chickens and ducks. PDRC found >99% accuracy in Type A and H5 detection, including from pooled cloacal swabs in ducks. Dr. Daniel Perez has presented results at the 15th International Seminar on Poultry Pathology and Production and FAO meetings.
• Royal GD (GD Animal Health)flagship / core strategic partnerStrategic or Co-development Partner · 1 January 2025Royal GD, based in Deventer, Netherlands, is one of the world's largest veterinary diagnostic laboratories (5M+ tests/year). Co-developed the Alveo Sense™ Poultry Avian Influenza Test combining Alveo's molecular platform with Royal GD's veterinary expertise. Collaboration is being expanded beyond avian influenza into additional notifiable disease and respiratory targets impacting poultry. Royal GD also serves as Alveo's Netherlands distributor and co-presents webinars (e.g., Professor Sjaak De Wit).
• U.S. Centers for Disease Control and Prevention (CDC)major reference / validation partnerOthers · 1 January 2025Alveo successfully fulfilled an expanded CDC milestone agreement to advance its rapid molecular test for detecting and differentiating between seasonal Influenzas A, B, and A(H5) in humans. The CDC relationship underpins Alveo's be.well® human-health diagnostics pipeline.
• Spectrum Scienceauthorized media relations partnerGTM or Marketing PartnerSpectrum Science is Alveo's authorized media relations partner. Media inquiries are routed to [email protected], supporting PR and earned-media activities around press releases, CEPI grant, Egypt deployment, PDRC results, and CDC milestones.
• Shehdula sh.p.kcountry distributor (albania)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Albania ([email protected], +355 694 093 809).
• Sia Hydroxcountry distributor (baltics)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Estonia, Latvia, and Lithuania ([email protected], +371 67551517).
• Biosan Kft.country distributor (hungary)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Hungary ([email protected], +36 70 312 93 73).
• InterPharm D.o.o.country distributor (montenegro)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Montenegro ([email protected], +382 20 675 090).
• Kubbar Internationalcountry distributor (kuwait)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Kuwait ([email protected], +971 42204761).
• Hivet Internationalcountry distributor (pakistan)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Pakistan ([email protected], +92 321 4380690).
• Ali Al Suwaidi Trading Establishment (ASTE)country distributor (qatar)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Qatar ([email protected], +974 44995121).
• Cyclopharma S.A.country distributor (morocco)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Morocco ([email protected], +212 5 20 30 11 90).
• Wafalabcountry distributor (tunisia)Channel Partner/ Reseller/ DistributorAlveo's authorized distributor in Tunisia ([email protected], +216 29 29 32 32).

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• Cepheid (Danaher): Established molecular diagnostics incumbent (GeneXpert system) with deep hospital, clinic, and reference-lab penetration. Directly comparable to Alveo as a molecular NAAT platform, but Cepheid operates at higher throughput and price points with a much larger installed base.
• Abbott (ID NOW): ID NOW is Abbott's rapid molecular point-of-care platform for influenza, RSV, and Strep A. Comparable to Alveo in delivering lab-grade molecular results at the point of need, but Abbott operates at far greater scale with established reimbursement and clinical channels.
• bioMérieux (BioFire): BioFire FilmArray is the leading syndromic molecular diagnostic panel in clinical labs and increasingly in decentralized settings. Comparable to Alveo as a multiplex NAAT platform, though BioFire targets higher-complexity clinical settings versus Alveo's field / point-of-need positioning.
• QuidelOrtho: QuidelOrtho (Triage MeterPro, Sofia, QuickVue) is a broad rapid-diagnostics incumbent with growing molecular and immunoassay offerings. Comparable to Alveo as a decentralized infectious-disease testing provider, but with deeper reimbursement, distribution, and clinical relationships.

Direct peers

• Mesa Labs / Mesa Biotech (acquired by Thermo Fisher Scientific): Acquired by Thermo Fisher in 2021, Mesa Biotech developed the Accula line of LAMP-based, palm-sized molecular diagnostics for point-of-care use — the closest historical analog to Alveo's be.well / Alveo Sense platform in chemistry, form factor, and target customer.
• Cue Health: Cue's portable, consumer- and clinician-facing molecular diagnostic platform (Cue Reader + test cartridges) targets respiratory pathogens at point-of-care. Closely comparable to be.well in form factor, cartridge model, and direct-to-provider GTM.
• Visby Medical: Visby develops single-use, palm-sized PCR diagnostic devices for infectious disease at point-of-care. Comparable to Alveo Sense as a portable molecular platform competing on miniaturization and time-to-result, with a similar hardware-plus-consumable revenue model.
• Lucira Health (now Pfizer): Lucira (acquired by Pfizer in 2023) developed a LAMP-based, single-use at-home molecular COVID and flu test. Directly comparable to Alveo's LAMP chemistry and decentralized-use model, illustrating both the opportunity and the execution risk for handheld molecular platforms.

Emerging players

• Co-Diagnostics (Codi): Co-Diagnostics develops and commercializes PCR and LAMP-based molecular diagnostics including the Logix Smart platform. Comparable to Alveo in LAMP chemistry and infectious-disease focus, though historically more concentrated on COVID and clinical lab use.
• T2 Biosystems: T2 develops proprietary molecular diagnostics platforms (T2 Magnetic Resonance) for sepsis and Candida directly from whole blood. Comparable to Alveo as a molecular platform company targeting decentralized, rapid diagnostics, though in a different clinical vertical.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/alveo-technologies

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries2 records

Funding overview

Funding rounds3 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Alveo Technologies